David Pohl clearly states the expertise of Dr. Falk " who contributes concerned business and shareholder input" Really PTSC....and you believe that Stan Caplan and Pete Lozano less qualifed?????

TWST: The company has five people at the present

time. Would you tell us about the backgrounds and expertise of

several of those five people, yourself included?

Mr. Pohl: I am an experienced business lawyer and have

been on the Board of Directors of Patriot Scientific since 2001. In addition

to myself, we are pleased to have other Board members who

contribute almost on a daily basis to the progress and growth of the

company. One of our Directors is an experienced CPA, Gloria Felcyn,

who serves as the Chairman of our Audit Committee. Another

Director is an attorney, Carlton Johnson, who is quite experienced in

legal matters. He helps us tremendously in that arena. We have, in the

past year, added James Turley to our Board. Jim is a recognized industry

authority on microprocessors and intellectual property, and so

he is providing very valuable input in that regard. And then we also

have Dr. Helmut Falk, who is an anesthesiologist, and who contributes

concerned business and shareholder input as the son of the

Founder of the company. That is our Board of Directors. In addition

to myself as the Chairman and CEO, our CFO is Tom Sweeney. Tom

is a CPA with a background in dealing with companies that are of an

entrepreneurial nature and publicly held companies that have experienced

rapid growth in the past. In addition to Tom and myself being

here in the office as executives on a daily basis, we have a very good

controller and two other assistants.

TWST: Do you expect to add some people as the company

becomes more successful?

Mr. Pohl: Absolutely, we look forward to that. At the same

time, we favor operating on a lean and mean basis, and that is the way

that we are able to function very effectively. My objective has always

been to minimize investments of the company in bricks and mortar

and to focus more on the revenue, particularly recurring revenue.

TWST: What occupies your own attention most on a

day-by-day basis?

Mr. Pohl: Certainly, attention to closely following the activities

of the licensing strategy that we are pursuing in addition to a

myriad of managerial activities associated with being the CEO of a

small team running a public company with a large number of shareholders.

Being a publicly held company, one of the things that I find

very interesting these days are the challenges that go with operating

a company in the era of Internet message boards. When you have a

small company, a small staff such as ours, and a very large widespread

shareholder group (as I indicated earlier, it’s probably around

16,000 in number), there are lots of ongoing promotional and investor

relations duties that fall on the CEO’s desk in a situation of

this sort, in addition to the daily tasks related to running a business.

TWST: What would be the two or three best reasons for

a long-term investor to take a very good look at Patriot Scientific?

Mr. Pohl:First of all, the value and strength of the patent

portfolio. If one considers simply the fact that we’ve put over 300

companies on notice so far, you can speculate that there are probably

several hundred more companies that might be added to the list in the

future. So the potential for licensing revenues is tremendous. One

could do some calculations on their own as far as picking a hypothetical

average revenue stream per individual license and then multiplying

that by the number of licenses they expect to see the

company have. In doing so, one can come up with some interesting

numbers of projected future revenue. As we accumulate that revenue,

investors can look at two things. Number one is that since we are a

company that has a stock that is currently trading at a price in the

range of near $0.80 a share and a market cap of almost $300 million,

we should have tremendous prospects for appreciation in the value of

the shares. In addition to that, because of the activities that I have described

in the revenue stream, the potential for dividends along with

the appreciation are great

TWST: Are you going to take any steps to improve your

capital structure?

Mr. Pohl: We have already taken some significant steps

in that, when this company was struggling to keep the doors open a

number of years ago, we had contracted for a line of credit — an

equity line of credit financing that later shifted into convertible

debentures. In March of this year, we paid off the last of the convertible

debentures, which had the result of the company basically

eliminating its long-term debt. So as far as strength is concerned, I

would certainly point to that. In addition to the strong revenue

stream that we have from licensing, we have a very small headcount

and low overhead. We are really at a point where the capital

structure is very favorable.

…..I feel that Patriot Scientific should be on

every investor’s radar screen.

TWST: Thank you.

http://www.ptsc.com/documentation/Patriot.pdf.